Search results for: “”

  • Ethical Funds

    Ethical Funds

    Ethical funds measure up in different ways, says Nick Sudbury. Some simply screen out the bad, while others actively support the good. But does…

  • Small is Beautiful

    Small is Beautiful

    The Joy of Investing in Smaller Company Funds isn’t Just About Better Returns, Says Simon Cordery, Head of Investor Relations for Investment…

  • Let Me Be Your Tech Department

    Let Me Be Your Tech Department

    A little something from SimplyBiz to brighten up a gloomy Tuesday: You never know what talents you’ll find in this profession. The attached…

  • Ayn Rand, Libertarian Beacon

    Ayn Rand, Libertarian Beacon

    Born 1905 in St Petersburg, Russia. Died 1982 in New York A Novelist as Economist? It’s just too easy to dismiss Ayn…

  • The Shipping Forecast

    The Shipping Forecast

    ‘Tis a Perfect Storm Coming, Me Hearties. Michael Wilson Checks Out the Dodgy Macro-Economic Omens From Bulk Carrier Rates I can tell…

  • Disclosure – Clarity Please

    Disclosure – Clarity Please

    The FCA’s latest review into disclosure doesn’t shed any new light, says Compliance Consultant Lee Werrell. Surely enough is enough? You’d think…

  • Discipline – How Much Is Too Much?

    Discipline – How Much Is Too Much?

    Peter Fitzgerald, Head of Multi-asset Funds at Aviva Investors, believes that flexible investment processes encouraging creativity and deeper portfolio understanding should prosper…

  • Two-Way Communications

    Two-Way Communications

    Part Seven of Abbie Tanner’s Marketing Innovation Engine™ Programme: Perfecting Your Client Communications Strategy How often do you communicate with your existing…

  • Aviva turns the commission taps off

    Aviva turns the commission taps off

       Laith Khalaf from Hargreaves Lansdown says that Aviva has just announced it will stop paying initial commission to company pension advisors from…

  • Neil Woodford on AstraZeneca

    Neil Woodford on AstraZeneca

    Neil Woodford, Head of Investment, Woodford Investment Management, comments on Pfizer’s recent bid for AstraZeneca Pfizer’s recent bid approach for AstraZeneca has presented…